These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 31727135)

  • 1. EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma.
    Xiao G; Jin LL; Liu CQ; Wang YC; Meng YM; Zhou ZG; Chen J; Yu XJ; Zhang YJ; Xu J; Zheng L
    J Immunother Cancer; 2019 Nov; 7(1):300. PubMed ID: 31727135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen receptor drives hepatocellular carcinogenesis by activating enhancer of zeste homolog 2-mediated Wnt/β-catenin signaling.
    Song H; Yu Z; Sun X; Feng J; Yu Q; Khan H; Zhu X; Huang L; Li M; Mok MTS; Cheng ASL; Gao Y; Feng H
    EBioMedicine; 2018 Sep; 35():155-166. PubMed ID: 30150059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EZH2 promotes hepatocellular carcinoma progression through modulating miR-22/galectin-9 axis.
    Chen S; Pu J; Bai J; Yin Y; Wu K; Wang J; Shuai X; Gao J; Tao K; Wang G; Li H
    J Exp Clin Cancer Res; 2018 Jan; 37(1):3. PubMed ID: 29316949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor-κB in hepatocellular carcinoma.
    Tsang DP; Wu WK; Kang W; Lee YY; Wu F; Yu Z; Xiong L; Chan AW; Tong JH; Yang W; Li MS; Lau SS; Li X; Lee SD; Yang Y; Lai PB; Yu DY; Xu G; Lo KW; Chan MT; Wang H; Lee TL; Yu J; Wong N; Yip KY; To KF; Cheng AS
    J Pathol; 2016 Apr; 238(5):651-64. PubMed ID: 26800240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-L1 expression in hepatocellular carcinoma (HCC) cells.
    Yan Y; Zheng L; Du Q; Yan B; Geller DA
    Cancer Immunol Immunother; 2020 Sep; 69(9):1891-1903. PubMed ID: 32377817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MYC inhibition increases PD-L1 expression induced by IFN-γ in hepatocellular carcinoma cells.
    Zou J; Zhuang M; Yu X; Li N; Mao R; Wang Z; Wang J; Wang X; Zhou H; Zhang L; Shi Y
    Mol Immunol; 2018 Sep; 101():203-209. PubMed ID: 30007230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Focal adhesion kinase depletion reduces human hepatocellular carcinoma growth by repressing enhancer of zeste homolog 2.
    Gnani D; Romito I; Artuso S; Chierici M; De Stefanis C; Panera N; Crudele A; Ceccarelli S; Carcarino E; D'Oria V; Porru M; Giorda E; Ferrari K; Miele L; Villa E; Balsano C; Pasini D; Furlanello C; Locatelli F; Nobili V; Rota R; Leonetti C; Alisi A
    Cell Death Differ; 2017 May; 24(5):889-902. PubMed ID: 28338656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CLDN14 is epigenetically silenced by EZH2-mediated H3K27ME3 and is a novel prognostic biomarker in hepatocellular carcinoma.
    Li CP; Cai MY; Jiang LJ; Mai SJ; Chen JW; Wang FW; Liao YJ; Chen WH; Jin XH; Pei XQ; Guan XY; Zeng MS; Xie D
    Carcinogenesis; 2016 Jun; 37(6):557-566. PubMed ID: 27207647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential roles of EZH2, Bmi-1 and miR-203 in cell proliferation and invasion in hepatocellular carcinoma cell line Hep3B.
    Yang F; Lv LZ; Cai QC; Jiang Y
    World J Gastroenterol; 2015 Dec; 21(47):13268-76. PubMed ID: 26715809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma Cell Polarization to the Immunoglobulin G Phenotype in Hepatocellular Carcinomas Involves Epigenetic Alterations and Promotes Hepatoma Progression in Mice.
    Wei Y; Lao XM; Xiao X; Wang XY; Wu ZJ; Zeng QH; Wu CY; Wu RQ; Chen ZX; Zheng L; Li B; Kuang DM
    Gastroenterology; 2019 May; 156(6):1890-1904.e16. PubMed ID: 30711627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The functional and mechanistic relatedness of EZH2 and menin in hepatocellular carcinoma.
    Gao SB; Xu B; Ding LH; Zheng QL; Zhang L; Zheng QF; Li SH; Feng ZJ; Wei J; Yin ZY; Hua X; Jin GH
    J Hepatol; 2014 Oct; 61(4):832-9. PubMed ID: 24845612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of the long non-coding RNA SPRY4-IT1 promotes tumor cell proliferation and invasion by activating EZH2 in hepatocellular carcinoma.
    Zhou M; Zhang XY; Yu X
    Biomed Pharmacother; 2017 Jan; 85():348-354. PubMed ID: 27899259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiR-137 suppresses migration and invasion by targeting EZH2-STAT3 signaling in human hepatocellular carcinoma.
    Huang B; Huang M; Li Q
    Pathol Res Pract; 2018 Dec; 214(12):1980-1986. PubMed ID: 30274685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis.
    Cheng AS; Lau SS; Chen Y; Kondo Y; Li MS; Feng H; Ching AK; Cheung KF; Wong HK; Tong JH; Jin H; Choy KW; Yu J; To KF; Wong N; Huang TH; Sung JJ
    Cancer Res; 2011 Jun; 71(11):4028-39. PubMed ID: 21512140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.
    Xu L; Beckebaum S; Iacob S; Wu G; Kaiser GM; Radtke A; Liu C; Kabar I; Schmidt HH; Zhang X; Lu M; Cicinnati VR
    J Hepatol; 2014 Mar; 60(3):590-8. PubMed ID: 24211739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TGF-β1-Induced SOX18 Elevation Promotes Hepatocellular Carcinoma Progression and Metastasis Through Transcriptionally Upregulating PD-L1 and CXCL12.
    Chen J; Feng W; Sun M; Huang W; Wang G; Chen X; Yin Y; Chen X; Zhang B; Nie Y; Fan D; Wu K; Xia L
    Gastroenterology; 2024 Jul; 167(2):264-280. PubMed ID: 38417530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The EGFR-P38 MAPK axis up-regulates PD-L1 through miR-675-5p and down-regulates HLA-ABC via hexokinase-2 in hepatocellular carcinoma cells.
    Liu Z; Ning F; Cai Y; Sheng H; Zheng R; Yin X; Lu Z; Su L; Chen X; Zeng C; Wang H; Liu L
    Cancer Commun (Lond); 2021 Jan; 41(1):62-78. PubMed ID: 34236149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma.
    Liu CQ; Xu J; Zhou ZG; Jin LL; Yu XJ; Xiao G; Lin J; Zhuang SM; Zhang YJ; Zheng L
    Br J Cancer; 2018 Jul; 119(1):80-88. PubMed ID: 29921949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Positive Correlation Between the EZH2 and PD-L1 Expression in Resected Lung Adenocarcinomas.
    Toyokawa G; Takada K; Tagawa T; Hamamoto R; Yamada Y; Shimokawa M; Oda Y; Maehara Y
    Ann Thorac Surg; 2019 Feb; 107(2):393-400. PubMed ID: 30343006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EZH2 Inhibition Enhances PD-L1 Protein Stability Through USP22-Mediated Deubiquitination in Colorectal Cancer.
    Huang J; Yin Q; Wang Y; Zhou X; Guo Y; Tang Y; Cheng R; Yu X; Zhang J; Huang C; Huang Z; Zhang J; Guo Z; Huo X; Sun Y; Li Y; Wang H; Yang J; Xue L
    Adv Sci (Weinh); 2024 Jun; 11(23):e2308045. PubMed ID: 38520088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.